Johnson & Johnson (JNJ) 100.25 $JNJ
Global and Chinese Monoclonal Antibody Industry Forecasts Report, 2013-2017
M2 - 2 hrs 4 mins ago
Research and Markets (http://www.researchandmarkets.com/research/9lnwhr/global_and) has announced the addition of the "Global and Chinese Monoclonal Antibody Industry Forecasts Report, 2013-2017" report to their offering. In September 2013, the Infliximab generic drug - Inflectra developed by South Korea Celltrion and the U.S. Hospira jointly was launched upon the approval of the EU EMA. In November 2013, the Trastuzumab generic drug developed by the U.S. Mylan and India Biocon together was available in the market under the permit of Drug Controller General Of India. Mylan will sell the product tagged with the brand name Hertraz in India in early 2014. In addition, India Biocon's first anti-CD6 Alzumab (Itolizumab) for the treatment of chronic plaque psoriasis was approved to be sold in India in August 2013. In recent years, China monoclonal antibody industry has been developing fast with the market size CAGR of 44.6% in 2010-2012. More than 100 companies have been involved in monoclonal antibody agents, and 10 ones of them have conducted clinical applications. The Chinese market is dominated by Rituximab, Trastuzumab, Infliximab, Bevacizumab and other imported products, all of which occupied 70-75% market share totally in 2012. However, by virtue of price and geographical advantages, the competitiveness of Chinese local monoclonal antibody products has been gradually improved, such as the competition between Nimotuzumab and Cetuximab. The market share of Merck's Cetuximab in China shrinks and was excluded from top 200 drugs purchased by Chinese 22 typical urban hospitals in 2012 with the value of RMB130 million (down 16.35% year on year). Meanwhile, the R & D of monoclonal antibody has also made progress. The Adalimumab generic drug developed by Huahai Pharmaceutical and American Oncobiologics jointly was ratified by the EU EMA and the U.S. FDA in December 2013 and the clinical trial Phase I was implemented. The Trastuzumab generic drug of Genor Biopharma was granted with Australian Clinical Preliminary Summary Report Phase I in August 2012 and SFDA's clinical trial approval in July 2013. The key topics covered by this report include: - Status quo, market size, competition pattern and development forecast of the global monoclonal antibody industry; - Status quo, market size, competition pattern and development forecast of China monoclonal antibody industry; - Operation, monoclonal antibody business, development in China and R & D of six global and 10 Chinese monoclonal antibody companies. Key Topics Covered: 1 Overview of Monoclonal Antibody Industry 2 Overview of Global Monoclonal Antibody Industry 3 Chinese Monoclonal Antibody Market 4 Key Foreign Monoclonal Antibody Agent Enterprises 5 Key Chinese Monoclonal Antibody Agent Enterprises 6 Summary and Forecast Companies Mentioned - AbbVie - Amgen - Beijing Biotech Pharmaceutical Co., Ltd. - Beijing SL Pharmaceutical Co., Ltd. - Chengdu Huasun Group Co., Ltd. - Huahai Pharmaceutical Co., Ltd. - Johnson & Johnson - Merck - NVS - Roche Pharmaceuticals - Shanghai CP GuoJian Biotech Academy - Shanghai CP Guojian Pharmaceutical Co., Ltd. - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. - Shanghai Guosheng Pharmaceutical Co., Ltd. - Shanghai Lansheng States Kin Pharmaceutical Co., Ltd. - Shanghai Medipharm Biotech Co., Ltd. - Shanghai Zhangjiang Biotech Co., Ltd. - Shenzhen Main Luck Pharmaceuticals Inc. - Yunnan Walvax Biotechnology Co., Ltd. - Zhejiang Hisun Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/9lnwhr/global_and
Final Glance: Pharmaceuticals companies
AP - Tue May 20, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Final Glance: Medical Devices companies
AP - Tue May 20, 5:02PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Midday Glance: Pharmaceuticals companies
AP - Tue May 20, 12:44PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Tue May 20, 12:44PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Why I'm Still Avoiding Dendreon
Brian Nichols, The Motley Fool - Motley Fool - Tue May 20, 11:36AM CDT
Investors sold the news of Dendreon 's first-quarter earnings and the company's very slight year-over-year revenue growth, although the stock has more recently risen on the announcement of a Provenge abstract presentation . With $68.8 million in...
Early Glance: Medical Devices companies
AP - Tue May 20, 9:40AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Early Glance: Pharmaceuticals companies
AP - Tue May 20, 9:40AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Global Point-of-Care Diagnostics Market Outlook 2014-2018 - United States Accounts for Almost 50% of Total Market
M2 - Tue May 20, 8:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fsn9b9/global) has announced the addition of the "Global Point-of-Care Diagnostics Market Outlook 2018" report to their offering. Point-of-care testing allows patient diagnoses in the physician's office, in an ambulance, at the home, on the field, or in the hospital. The results of care are timely, and allow rapid treatment for the patient, significantly impacting delivery of healthcare. Technological aid by advanced microfluidics, digital optics, lab-on-a-chip experiments, and devices is expected to further enhance the quality of POCT. Backed by such factors the market for global POCT is expected to grow at a CAGR of around 8.4% during 2013-2018 to reach a value of US$ 24 Billion by 2018. According to Global Point-of-Care Diagnostics Market Outlook 2018, the global POCT industry is at a very crucial stage with POCT expanding itself into diverse disease areas, such as cancer and HIV diagnostics. The coming years will witness POCT take over routine diagnostics, as the focus shifts from curative to preventive care with enhanced patient involvement. Currently, the United States accounts for almost 50% of the total POCT market, followed by regions, such as Europe and Japan. In these developed regions, the proliferation of transportable, portable and handheld instruments along with ever-increasing incidence of lifestyle related disorders, such as diabetes has supported the growth of Point of Care testing. At the same time, rapid advancements in technology and infrastructure and the availability of diagnostic systems that cannot be employed in resource limited settings will result in enhanced uptake of POCT in emerging nations. The report provides a brief outlook of the IVD industry, covering major aspects, such as current market size, future growth and current and future geographical segmentation. It also talks about the major players of IVD industry and their respective contribution to the current market. Next, we have covered the POCT industry in depth, estimating the current and future market and tracking the recent developments that have taken place. A geographical segmentation of the POCT market is next in line with current estimates and future forecasts for major geographies. In every region, an opportunity assessment based on disease demographics for POCT players has been done. Key Trends - POCT: Expanding Avenues into Multiple Disease Diagnosis - Mobile Apps Expanding into POC - POCT Tests for HIV Diagnosis on a Rise - POC Tests, a Non-Invasive Alternative for Non-communicable Diseases Key Topics Covered: 1. Analyst View 2. Research Methodology 3. In Vitro Diagnostic Market Overview 4. Point-of-Care Diagnostics Market Outlook 2018 5. Geographical Segmentation 6. Industry Trends and Developments 7. Competitive Landscape - Abbott Laboratories - Alere - Bayer HealthCare - Beckman Coulter - Becton Dickinson - Bio-Rad - Johnson and Johnson - Medtronic - Roche Holding Ltd. - Siemens HealthCare For more information visit http://www.researchandmarkets.com/research/fsn9b9/global
Global Cosmeceuticals Market Outlook 2018 - Forecasts & Opportunities for the $35 Billion Industry
M2 - Tue May 20, 8:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/55zhfq/global) has announced the addition of the "Global Cosmeceuticals Market Outlook 2018" report to their offering. The market was estimated at US $35 Billion and is likely to augment at a CAGR of around 7% during 2013-2018. Cosmeceuticals have become the fastest growing segment of the Cosmetics and Personal Care Industry. These products are described as cosmetic products with drug-like benefits and are the recent addition to the Cosmetics Industry. With increasing fascination among people to look young and the global population's increasing median age, the cosmeceuticals product market is growing at a significant rate. Advancements in technology and emergence of new and herbal ingredients have further contributed to the progress in the commercialization of cosmeceutical products worldwide. The global cosmeceutical market will witness the emergence of various new trends around the world. The rising rate at which cosmeceuticals are being adopted is fuelling the demand for natural active ingredients, paving way for plant stem cells. The report, Global Cosmeceuticals Market Outlook 2018 provides an insight into more such trends in the coming few years which will help revolutionize the perception about cosmeceuticals. The report has been divided into various chapters which provide a detailed account of the current and future markets. The cosmeceutical industry has been segmented into various broad heads such as skin care, hair care, injectables etc., which have been further broken into segments such as anti aging, anti acne, and sun protection. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Global Cosmeceuticals Overview - Antioxidants - Enzymes - Proteins & Peptides - Botanical Actives - Other Cosmeceutical Chemicals 4. Market Drivers and Trends - Plant Stem Cells Bringing Revolution in Skin Care - BB and CC Creams, the All in One Package Gaining Popularity - Market Players to Capture the Growth Opportunities in Emerging Markets - Chemicals being Ditched for Organic Cosmeceuticals 5. Market Outlook 2018 - Skin Care - Hair Care - Injectable - Others Cosmeceuticals Products 6. Country-level Market Assessment - US - Europe - China - India - Japan - Brazil 7. Competitive Landscape - Croda International Plc - Johnson & Johnson - Bayer - L'Or?al - Procter & Gamble - Avon - Shiseido For more information visit http://www.researchandmarkets.com/research/55zhfq/global
Whistleblower Payments Top $300 Million Under False Claims Act in Fiscal Year 2014
PRWeb - Tue May 20, 2:27AM CDT
A review of press releases issued by the Department of Justice since October 1, 2013 conducted by Young Law Group reveals that whistleblowers have been awarded more than $300 million from settlements in qui tam lawsuits in the current fiscal year. The federal government's fiscal year begins on October 1st, leaving more than four months left to add to the impressive amount so far.
Minnesota bans anti-bacterial chemical from soaps
By STEVE KARNOWSKI - AP - Mon May 19, 5:22PM CDT
MINNEAPOLIS (AP) — It's widely used nationwide as a germ-killing ingredient in soaps, deodorants and even toothpaste, but it's being banned in Minnesota.
Jazz Pharmaceuticals Names Russell J. Cox To Position Of Chief Operating Officer
PR Newswire - Mon May 19, 1:00PM CDT
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of Russell J. Cox to the newly created position of chief operating officer (COO). Mr. Cox, who joined Jazz Pharmaceuticals in July 2010, most recently served as executive vice president and chief commercial officer at the company. He will continue to report to Bruce Cozadd, chairman and chief executive officer, and will now have global responsibility for the commercial, research and development (R&D) and technical operations organizations.
Global Anti-Aging Product Market 2014-2018: Beiersdorf AG, L'Oreal, Phosphagenics, Procter & Gamble & Unilever Group Dominate the Market
M2 - Mon May 19, 8:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/76jcqj/global_antiaging) has announced the addition of the "Global Anti-Aging Product Market 2014-2018" report to their offering. The analysts forecast the Global Anti-aging Product market will grow at a CAGR of 6.7% over the period 2013-2018. One of the main drivers is the rising global aging population. This growth is resulting in an increase in the need for anti-aging and age-defying facial products. Consumers are increasingly using anti-aging products made from natural and organic ingredients. Over the years, consumers have started seeking safe products and are now paying more attention to the ingredients in the anti-aging products, preferring those that do not contain chemicals or ingredients that could cause harmful side effects. Typically, anti-aging skincare and hair care products are made from synthetic ingredients, additives, and fillers. Such products could harm skin and hair, or even weaken and loosen skin when it starts aging. Natural oils such as argan, marula, coconut, and almond are some popular ingredients used in organic products. As organic products have little harmful effects, many large companies are launching natural and organic products to gain more market share. Further, the report states that one of the main challenges hindering market growth is the intensifying competition in the market caused by the entrance of new players and private labels. Key Vendors - Beiersdorf AG - L'Or?al SA - Phosphagenics Ltd. - Procter & Gamble Co. - Unilever Group Other Prominent Vendors - Allergan Inc. - Amexdrug Corp. - Avon Products Inc. - Chanel SA - Christian Dior SA - Clarins USA Inc. - DS Healthcare Group Inc. - Elizabeth Arden Inc. - Ella Bach? - Est?e Lauder Co. Inc. - Henkel AG & Co KGaA - Jan Marini Skin Research Inc. - Johnson & Johnson Co. - Kao Corp. - NeoStrata Co. - NuSKin Enterprises - Orlane SA - Revlon Inc. - Robanda International Inc. - Shiseido Co. - SkinMedica Inc. - Skinvisible Inc. - Woodridge Labs Inc. For more information visit http://www.researchandmarkets.com/research/76..._antiaging
1 Biotech Refusing to Stick Its Neck Out
Cory Renauer, The Motley Fool - Motley Fool - Mon May 19, 8:30AM CDT
Pharmacyclics confused the market earlier this month with some shockingly conservative Imbruvica guidance. Sales of the breakthrough leukemia therapy have rocketed upwards since its launch late last year, so the suggestion that it will level off...
Research and Markets: Remicade (Ulcerative Colitis) - Forecast and Market Analysis to 2022
Business Wire - Mon May 19, 7:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bshw3d/remicade) has announced the addition of the "Remicade (Ulcerative Colitis) - Forecast and Market Analysis to 2022" report to their offering.
Research and Markets: Kappaproct (Ulcerative Colitis) - Forecast and Market Analysis to 2022
Business Wire - Mon May 19, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q4qb8z/kappaproct) has announced the addition of the "Kappaproct (Ulcerative Colitis) - Forecast and Market Analysis to 2022" report to their offering.
Emmi Solutions Shares Best Practices and Outcomes at Patient Experience Summit
Marketwire - Mon May 19, 6:30AM CDT
Emmi Solutions, a leader in outcomes-driven patient engagement, will be leading multiple discussions and presenting original research at Cleveland Clinic's "2014 Patient Experience: Empathy + Innovation Summit". The conference brings together patient experience leaders, healthcare CEOs, nursing leaders, policy makers and major stakeholders for presentations, debate and candid discussion of key strategies that drive patient experience and engagement.
Global Abdominal Obesity Clinical Trials Review 2014
M2 - Mon May 19, 5:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qkc4ph/abdominal_obesity) has announced the addition of the "Abdominal Obesity Global Clinical Trials Review, H1, 2014" report to their offering. This report provides elemental information and data relating to the clinical trials on Abdominal Obesity. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Abdominal Obesity. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Genfit SA - Lithera, Inc. - AstraZeneca PLC - Sanofi - Novartis AG - Hanmi Science Co., Ltd. - Parry Nutraceuticals - Kythera Biopharmaceuticals, Inc. - Johnson & Johnson - Queen's University - Massachusetts General Hospital - University of Pittsburgh - Wake Forest University - Baker IDI Heart and Diabetes Institute - Rush University Medical Center - UMC Utrecht Holding BV - Southeast University - Washington University School of Medicine - Maastricht University Medical Center For more information visit http://www.researchandmarkets.com/research/qk...al_obesity
Remicade (Ulcerative Colitis) - Forecast and Market Analysis to 2022
M2 - Mon May 19, 4:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rhzq3p/remicade) has announced the addition of the "Remicade (Ulcerative Colitis) - Forecast and Market Analysis to 2022" report to their offering. During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's (J&J's) Simponi and Takeda's Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively. Remicade (infliximab) is a TNF-a inhibitor that was originally developed by Centocor Ortho Biotech, which is now Janssen Biotech, a subsidiary of J&J. Upon the onset of intestinal inflammation in IBD, a rather aggravated immune response is initiated that is skewed towards a specific T-cell phenotype. This T-cell group (Th1) is attracted to the site of inflammation, where additional white blood cells are recruited. Th1 cells produce large amounts of an inflammatory protein called INF-?, which, in turn, induces the production of the pro-inflammatory cytokine TNF-a in both local and recruited macrophages, as well as in the intestinal epithelial cells Key Topics Covered: 1 Table of Contents 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Remicade (infliximab) 7 Appendix For more information visit http://www.researchandmarkets.com/research/rhzq3p/remicade About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global and Chinese Monoclonal Antibody Industry Forecasts Report, 2013-2017
M2 - 2 hrs 4 mins ago
Research and Markets (http://www.researchandmarkets.com/research/9lnwhr/global_and) has announced the addition of the "Global and Chinese Monoclonal Antibody Industry Forecasts Report, 2013-2017" report to their offering. In September 2013, the Infliximab generic drug - Inflectra developed by South Korea Celltrion and the U.S. Hospira jointly was launched upon the approval of the EU EMA. In November 2013, the Trastuzumab generic drug developed by the U.S. Mylan and India Biocon together was available in the market under the permit of Drug Controller General Of India. Mylan will sell the product tagged with the brand name Hertraz in India in early 2014. In addition, India Biocon's first anti-CD6 Alzumab (Itolizumab) for the treatment of chronic plaque psoriasis was approved to be sold in India in August 2013. In recent years, China monoclonal antibody industry has been developing fast with the market size CAGR of 44.6% in 2010-2012. More than 100 companies have been involved in monoclonal antibody agents, and 10 ones of them have conducted clinical applications. The Chinese market is dominated by Rituximab, Trastuzumab, Infliximab, Bevacizumab and other imported products, all of which occupied 70-75% market share totally in 2012. However, by virtue of price and geographical advantages, the competitiveness of Chinese local monoclonal antibody products has been gradually improved, such as the competition between Nimotuzumab and Cetuximab. The market share of Merck's Cetuximab in China shrinks and was excluded from top 200 drugs purchased by Chinese 22 typical urban hospitals in 2012 with the value of RMB130 million (down 16.35% year on year). Meanwhile, the R & D of monoclonal antibody has also made progress. The Adalimumab generic drug developed by Huahai Pharmaceutical and American Oncobiologics jointly was ratified by the EU EMA and the U.S. FDA in December 2013 and the clinical trial Phase I was implemented. The Trastuzumab generic drug of Genor Biopharma was granted with Australian Clinical Preliminary Summary Report Phase I in August 2012 and SFDA's clinical trial approval in July 2013. The key topics covered by this report include: - Status quo, market size, competition pattern and development forecast of the global monoclonal antibody industry; - Status quo, market size, competition pattern and development forecast of China monoclonal antibody industry; - Operation, monoclonal antibody business, development in China and R & D of six global and 10 Chinese monoclonal antibody companies. Key Topics Covered: 1 Overview of Monoclonal Antibody Industry 2 Overview of Global Monoclonal Antibody Industry 3 Chinese Monoclonal Antibody Market 4 Key Foreign Monoclonal Antibody Agent Enterprises 5 Key Chinese Monoclonal Antibody Agent Enterprises 6 Summary and Forecast Companies Mentioned - AbbVie - Amgen - Beijing Biotech Pharmaceutical Co., Ltd. - Beijing SL Pharmaceutical Co., Ltd. - Chengdu Huasun Group Co., Ltd. - Huahai Pharmaceutical Co., Ltd. - Johnson & Johnson - Merck - NVS - Roche Pharmaceuticals - Shanghai CP GuoJian Biotech Academy - Shanghai CP Guojian Pharmaceutical Co., Ltd. - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. - Shanghai Guosheng Pharmaceutical Co., Ltd. - Shanghai Lansheng States Kin Pharmaceutical Co., Ltd. - Shanghai Medipharm Biotech Co., Ltd. - Shanghai Zhangjiang Biotech Co., Ltd. - Shenzhen Main Luck Pharmaceuticals Inc. - Yunnan Walvax Biotechnology Co., Ltd. - Zhejiang Hisun Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/9lnwhr/global_and
Final Glance: Pharmaceuticals companies
AP - Tue May 20, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Final Glance: Medical Devices companies
AP - Tue May 20, 5:02PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Midday Glance: Pharmaceuticals companies
AP - Tue May 20, 12:44PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Tue May 20, 12:44PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Why I'm Still Avoiding Dendreon
Brian Nichols, The Motley Fool - Motley Fool - Tue May 20, 11:36AM CDT
Investors sold the news of Dendreon 's first-quarter earnings and the company's very slight year-over-year revenue growth, although the stock has more recently risen on the announcement of a Provenge abstract presentation . With $68.8 million in...
Early Glance: Medical Devices companies
AP - Tue May 20, 9:40AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Early Glance: Pharmaceuticals companies
AP - Tue May 20, 9:40AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Global Point-of-Care Diagnostics Market Outlook 2014-2018 - United States Accounts for Almost 50% of Total Market
M2 - Tue May 20, 8:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fsn9b9/global) has announced the addition of the "Global Point-of-Care Diagnostics Market Outlook 2018" report to their offering. Point-of-care testing allows patient diagnoses in the physician's office, in an ambulance, at the home, on the field, or in the hospital. The results of care are timely, and allow rapid treatment for the patient, significantly impacting delivery of healthcare. Technological aid by advanced microfluidics, digital optics, lab-on-a-chip experiments, and devices is expected to further enhance the quality of POCT. Backed by such factors the market for global POCT is expected to grow at a CAGR of around 8.4% during 2013-2018 to reach a value of US$ 24 Billion by 2018. According to Global Point-of-Care Diagnostics Market Outlook 2018, the global POCT industry is at a very crucial stage with POCT expanding itself into diverse disease areas, such as cancer and HIV diagnostics. The coming years will witness POCT take over routine diagnostics, as the focus shifts from curative to preventive care with enhanced patient involvement. Currently, the United States accounts for almost 50% of the total POCT market, followed by regions, such as Europe and Japan. In these developed regions, the proliferation of transportable, portable and handheld instruments along with ever-increasing incidence of lifestyle related disorders, such as diabetes has supported the growth of Point of Care testing. At the same time, rapid advancements in technology and infrastructure and the availability of diagnostic systems that cannot be employed in resource limited settings will result in enhanced uptake of POCT in emerging nations. The report provides a brief outlook of the IVD industry, covering major aspects, such as current market size, future growth and current and future geographical segmentation. It also talks about the major players of IVD industry and their respective contribution to the current market. Next, we have covered the POCT industry in depth, estimating the current and future market and tracking the recent developments that have taken place. A geographical segmentation of the POCT market is next in line with current estimates and future forecasts for major geographies. In every region, an opportunity assessment based on disease demographics for POCT players has been done. Key Trends - POCT: Expanding Avenues into Multiple Disease Diagnosis - Mobile Apps Expanding into POC - POCT Tests for HIV Diagnosis on a Rise - POC Tests, a Non-Invasive Alternative for Non-communicable Diseases Key Topics Covered: 1. Analyst View 2. Research Methodology 3. In Vitro Diagnostic Market Overview 4. Point-of-Care Diagnostics Market Outlook 2018 5. Geographical Segmentation 6. Industry Trends and Developments 7. Competitive Landscape - Abbott Laboratories - Alere - Bayer HealthCare - Beckman Coulter - Becton Dickinson - Bio-Rad - Johnson and Johnson - Medtronic - Roche Holding Ltd. - Siemens HealthCare For more information visit http://www.researchandmarkets.com/research/fsn9b9/global
Global Cosmeceuticals Market Outlook 2018 - Forecasts & Opportunities for the $35 Billion Industry
M2 - Tue May 20, 8:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/55zhfq/global) has announced the addition of the "Global Cosmeceuticals Market Outlook 2018" report to their offering. The market was estimated at US $35 Billion and is likely to augment at a CAGR of around 7% during 2013-2018. Cosmeceuticals have become the fastest growing segment of the Cosmetics and Personal Care Industry. These products are described as cosmetic products with drug-like benefits and are the recent addition to the Cosmetics Industry. With increasing fascination among people to look young and the global population's increasing median age, the cosmeceuticals product market is growing at a significant rate. Advancements in technology and emergence of new and herbal ingredients have further contributed to the progress in the commercialization of cosmeceutical products worldwide. The global cosmeceutical market will witness the emergence of various new trends around the world. The rising rate at which cosmeceuticals are being adopted is fuelling the demand for natural active ingredients, paving way for plant stem cells. The report, Global Cosmeceuticals Market Outlook 2018 provides an insight into more such trends in the coming few years which will help revolutionize the perception about cosmeceuticals. The report has been divided into various chapters which provide a detailed account of the current and future markets. The cosmeceutical industry has been segmented into various broad heads such as skin care, hair care, injectables etc., which have been further broken into segments such as anti aging, anti acne, and sun protection. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Global Cosmeceuticals Overview - Antioxidants - Enzymes - Proteins & Peptides - Botanical Actives - Other Cosmeceutical Chemicals 4. Market Drivers and Trends - Plant Stem Cells Bringing Revolution in Skin Care - BB and CC Creams, the All in One Package Gaining Popularity - Market Players to Capture the Growth Opportunities in Emerging Markets - Chemicals being Ditched for Organic Cosmeceuticals 5. Market Outlook 2018 - Skin Care - Hair Care - Injectable - Others Cosmeceuticals Products 6. Country-level Market Assessment - US - Europe - China - India - Japan - Brazil 7. Competitive Landscape - Croda International Plc - Johnson & Johnson - Bayer - L'Or?al - Procter & Gamble - Avon - Shiseido For more information visit http://www.researchandmarkets.com/research/55zhfq/global
Whistleblower Payments Top $300 Million Under False Claims Act in Fiscal Year 2014
PRWeb - Tue May 20, 2:27AM CDT
A review of press releases issued by the Department of Justice since October 1, 2013 conducted by Young Law Group reveals that whistleblowers have been awarded more than $300 million from settlements in qui tam lawsuits in the current fiscal year. The federal government's fiscal year begins on October 1st, leaving more than four months left to add to the impressive amount so far.
Minnesota bans anti-bacterial chemical from soaps
By STEVE KARNOWSKI - AP - Mon May 19, 5:22PM CDT
MINNEAPOLIS (AP) — It's widely used nationwide as a germ-killing ingredient in soaps, deodorants and even toothpaste, but it's being banned in Minnesota.
Jazz Pharmaceuticals Names Russell J. Cox To Position Of Chief Operating Officer
PR Newswire - Mon May 19, 1:00PM CDT
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of Russell J. Cox to the newly created position of chief operating officer (COO). Mr. Cox, who joined Jazz Pharmaceuticals in July 2010, most recently served as executive vice president and chief commercial officer at the company. He will continue to report to Bruce Cozadd, chairman and chief executive officer, and will now have global responsibility for the commercial, research and development (R&D) and technical operations organizations.
Global Anti-Aging Product Market 2014-2018: Beiersdorf AG, L'Oreal, Phosphagenics, Procter & Gamble & Unilever Group Dominate the Market
M2 - Mon May 19, 8:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/76jcqj/global_antiaging) has announced the addition of the "Global Anti-Aging Product Market 2014-2018" report to their offering. The analysts forecast the Global Anti-aging Product market will grow at a CAGR of 6.7% over the period 2013-2018. One of the main drivers is the rising global aging population. This growth is resulting in an increase in the need for anti-aging and age-defying facial products. Consumers are increasingly using anti-aging products made from natural and organic ingredients. Over the years, consumers have started seeking safe products and are now paying more attention to the ingredients in the anti-aging products, preferring those that do not contain chemicals or ingredients that could cause harmful side effects. Typically, anti-aging skincare and hair care products are made from synthetic ingredients, additives, and fillers. Such products could harm skin and hair, or even weaken and loosen skin when it starts aging. Natural oils such as argan, marula, coconut, and almond are some popular ingredients used in organic products. As organic products have little harmful effects, many large companies are launching natural and organic products to gain more market share. Further, the report states that one of the main challenges hindering market growth is the intensifying competition in the market caused by the entrance of new players and private labels. Key Vendors - Beiersdorf AG - L'Or?al SA - Phosphagenics Ltd. - Procter & Gamble Co. - Unilever Group Other Prominent Vendors - Allergan Inc. - Amexdrug Corp. - Avon Products Inc. - Chanel SA - Christian Dior SA - Clarins USA Inc. - DS Healthcare Group Inc. - Elizabeth Arden Inc. - Ella Bach? - Est?e Lauder Co. Inc. - Henkel AG & Co KGaA - Jan Marini Skin Research Inc. - Johnson & Johnson Co. - Kao Corp. - NeoStrata Co. - NuSKin Enterprises - Orlane SA - Revlon Inc. - Robanda International Inc. - Shiseido Co. - SkinMedica Inc. - Skinvisible Inc. - Woodridge Labs Inc. For more information visit http://www.researchandmarkets.com/research/76..._antiaging
1 Biotech Refusing to Stick Its Neck Out
Cory Renauer, The Motley Fool - Motley Fool - Mon May 19, 8:30AM CDT
Pharmacyclics confused the market earlier this month with some shockingly conservative Imbruvica guidance. Sales of the breakthrough leukemia therapy have rocketed upwards since its launch late last year, so the suggestion that it will level off...
Research and Markets: Remicade (Ulcerative Colitis) - Forecast and Market Analysis to 2022
Business Wire - Mon May 19, 7:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bshw3d/remicade) has announced the addition of the "Remicade (Ulcerative Colitis) - Forecast and Market Analysis to 2022" report to their offering.
Research and Markets: Kappaproct (Ulcerative Colitis) - Forecast and Market Analysis to 2022
Business Wire - Mon May 19, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q4qb8z/kappaproct) has announced the addition of the "Kappaproct (Ulcerative Colitis) - Forecast and Market Analysis to 2022" report to their offering.
Emmi Solutions Shares Best Practices and Outcomes at Patient Experience Summit
Marketwire - Mon May 19, 6:30AM CDT
Emmi Solutions, a leader in outcomes-driven patient engagement, will be leading multiple discussions and presenting original research at Cleveland Clinic's "2014 Patient Experience: Empathy + Innovation Summit". The conference brings together patient experience leaders, healthcare CEOs, nursing leaders, policy makers and major stakeholders for presentations, debate and candid discussion of key strategies that drive patient experience and engagement.
Global Abdominal Obesity Clinical Trials Review 2014
M2 - Mon May 19, 5:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qkc4ph/abdominal_obesity) has announced the addition of the "Abdominal Obesity Global Clinical Trials Review, H1, 2014" report to their offering. This report provides elemental information and data relating to the clinical trials on Abdominal Obesity. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Abdominal Obesity. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Genfit SA - Lithera, Inc. - AstraZeneca PLC - Sanofi - Novartis AG - Hanmi Science Co., Ltd. - Parry Nutraceuticals - Kythera Biopharmaceuticals, Inc. - Johnson & Johnson - Queen's University - Massachusetts General Hospital - University of Pittsburgh - Wake Forest University - Baker IDI Heart and Diabetes Institute - Rush University Medical Center - UMC Utrecht Holding BV - Southeast University - Washington University School of Medicine - Maastricht University Medical Center For more information visit http://www.researchandmarkets.com/research/qk...al_obesity
Remicade (Ulcerative Colitis) - Forecast and Market Analysis to 2022
M2 - Mon May 19, 4:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rhzq3p/remicade) has announced the addition of the "Remicade (Ulcerative Colitis) - Forecast and Market Analysis to 2022" report to their offering. During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's (J&J's) Simponi and Takeda's Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively. Remicade (infliximab) is a TNF-a inhibitor that was originally developed by Centocor Ortho Biotech, which is now Janssen Biotech, a subsidiary of J&J. Upon the onset of intestinal inflammation in IBD, a rather aggravated immune response is initiated that is skewed towards a specific T-cell phenotype. This T-cell group (Th1) is attracted to the site of inflammation, where additional white blood cells are recruited. Th1 cells produce large amounts of an inflammatory protein called INF-?, which, in turn, induces the production of the pro-inflammatory cytokine TNF-a in both local and recruited macrophages, as well as in the intestinal epithelial cells Key Topics Covered: 1 Table of Contents 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Remicade (infliximab) 7 Appendix For more information visit http://www.researchandmarkets.com/research/rhzq3p/remicade About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
